Generic and branded drugs for the treatment of people living with HIV/AIDS.

Journal Article (Review)

HIV/AIDS care has benefited tremendously from the availability of antiretroviral (ARV) drugs, both branded and generic. Drug discovery and innovation is the result of direct investment in the development of branded medications, a crucial process for future improvements in care. However, the cost of branded medications is too high for resource-limited countries, where most persons with HIV/AIDS live. Generic drugs dramatically lower the cost of care; however, their safety and efficacy must be ensured and maintained. Proven bioavailability and bioequivalence, in addition to satisfactory manufacturing, distribution, and administration, are keys to successfully implementing the use of qualified generic ARVs. Agencies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMEA), and the World Health Organization (WHO), continue to strengthen the surveillance process through which qualified generic and branded drugs are provided worldwide. Generic drugs have the potential to cause harm if rigorous standards for their use are not followed, but those that are qualified offer great promise in the treatment of HIV/AIDS.

Full Text

Duke Authors

Cited Authors

  • Bartlett, JA; Muro, EP

Published Date

  • March 2007

Published In

Volume / Issue

  • 6 / 1

Start / End Page

  • 15 - 23

PubMed ID

  • 17329500

International Standard Serial Number (ISSN)

  • 1545-1097

Digital Object Identifier (DOI)

  • 10.1177/1545109707299856

Language

  • eng

Conference Location

  • United States